Clean Science and Technology Limited reported its highest-ever consolidated sales in Q1FY27, reaching ₹2,684.32 million, a 10.5% year-on-year increase from ₹2,428.69 million in Q1FY26. While standalone revenue declined 5.8% to ₹2,071.04 million due to global headwinds, the consolidated group delivered robust growth driven by its subsidiary, Clean Fino-Chem Limited. Consolidated net profit rose 4.7% to ₹733.50 million, compared to ₹700.63 million in the prior year. The Board of Directors approved these unaudited results on August 1, 2026, following a limited review by statutory auditors Price Waterhouse Chartered Accountants LLP.

Financial Performance

The divergence between standalone and consolidated figures highlights the growing contribution of subsidiaries. Standalone EBITDA margin contracted to 42.7% from 46.4% in Q1FY26, while consolidated EBITDA margin stood at 36.5%, down from 41.6%. However, consolidated profit before tax (PBT) grew 3.2% to ₹975.51 million. Other income provided a significant buffer, contributing ₹213.85 million to standalone total income, up from ₹129.24 million previously.

Raw material costs accounted for 34.6% of standalone revenue, up from 32.5% in Q1FY26. Power and fuel costs rose to 10.8% from 9.2%. Despite these pressures, the company maintained a zero-debt status and strong return on capital employed (RoCE) of 39.4% for FY26.

Strategic Initiatives and Capex

Clean Science incurred approximately ₹1,000 crore in capital expenditure during Q1FY27, primarily invested in Clean Fino-Chem Limited. The company is establishing a wholly-owned subsidiary in the Netherlands, potentially named Clean Science BV, with an initial capital infusion of EUR 50,000. This entity will focus on distributing specialty chemicals in Europe, strengthening customer proximity and accelerating global growth. Additionally, Performance Chemical 2 is expected to be commercialized by Q3FY27.

What the Numbers Show

The company’s strategy of diversifying through subsidiaries is yielding tangible results. While the parent entity faced margin compression due to higher input costs, the consolidated group achieved record sales. The strategic collaboration with Swiss technology partner Geneus Chem AG has helped de-risk product concentration; the top four legacy products’ contribution declined from ~85% in Q4FY23 to ~60% in Q1FY27. HALS now accounts for 22% of sales, indicating successful portfolio expansion into high-value specialty chemicals.

Clean Science & Technology Limited has entered into a strategic long-term supply arrangement with Kemin Industries, securing a multi-year partnership that enhances the company’s position in the food and feed ingredient market. The agreement, effective from August 1, 2026, establishes Clean Science as a substantial primary supplier for Kemin, providing greater revenue visibility and aligning with the company’s broader business strategy.

The collaboration spans an initial term of five years, during which Clean Science will supply key ingredients essential to Kemin’s operations in the food and feed sector. This move underscores Clean Science’s focus on building durable relationships with global industry leaders while leveraging its manufacturing capabilities to meet consistent demand.

Deal Highlights

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring timely disclosure to stakeholders. Ruchita Vij, Company Secretary and Compliance Officer, signed the intimation filed with both BSE Limited and the National Stock Exchange of India Limited.

Strategic Implications

This partnership reflects a deliberate shift toward long-term contractual stability rather than spot-market transactions. By positioning itself as a primary supplier, Clean Science reduces customer acquisition costs over the contract period and gains deeper integration into Kemin’s supply chain. For investors, this signals reduced operational volatility and a clearer path to sustained volume growth in the specialty chemicals segment.

The absence of disclosed financial values suggests the agreement may be structured on a take-or-pay or forecast-based model, common in long-term industrial supply contracts. However, the explicit mention of “substantial primary supplier” status indicates significant volume commitments, which should translate into meaningful top-line contributions over the five-year horizon.

What the Numbers Show

While no monetary figures were disclosed in the filing, the structural nature of the deal — a five-year term with primary supplier designation — implies a material shift in Clean Science’s revenue mix. Historically reliant on shorter-term engagements, this arrangement likely improves predictability in cash flows and inventory planning. Analysts will monitor subsequent quarterly reports for early signs of volume ramp-up and margin impact from this partnership.